EGFR and non-small cell lung carcinoma: Therefore, a novel biomarker panel consisting of combination of CTC levels in blood and mRNA markers in saliva (CCNI, EGFR, FGF19, FRS2, GREB1) could discriminate NSCLC from healthy controls [15].